Additional possible mechanisms of the action of ocrelizumab in multiple sclerosis on example of a case-report

Close metadata

Recommended articles:

Biobanking in clinical trials involving multiple sclerosis patients. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(7-2):7-15

The diagnostic effectiveness of criteria for neuromyelitis optica spectrum disorders in the Russian clinical practice. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(7-2):16-25

Adherence to treatment in the management of patients with multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(7-2):26-32

Optimal patient profile for ofatumumab treatment: analysis of Russian data from the Phase 3 study. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(7-2):37-42

The effect of pregnancy on multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(7-2):43-49

The central vein sign in the differential diagnosis of multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(7-2):58-65

Possibilities of magnetic resonance morphometry and laboratory biomarkers in studying the progression of multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(7-2):66-71

Questionnaires for arm function assessment in patients with multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(6):36-42

Features of primary forms of headache in multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(6):70-73

Neurofilament light chain: a diagnostic potential for multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(6):115-119

Anti-B-cells products, including the anti-CD20 monoclonal antibody ocrelizumab, are widely coming to multiple sclerosis (MS) therapy. Its clinical-MRI efficacy in MS with relapses as well in primary progressive MS (PPMS) was proved by three phase III clinical studies. One example of the use of ocrelizumab use in aggressive MS showed the possibility of action on the leptomeningeal folliculi, seen at contract-enhancing MRI images.

Keywords:

multiple sclerosis

B-cells

ocrelizumab

meningeal folliculi

Authors:

Boĭko O.V.

Moskovskiĭ gorodskoĭ tsentr rasseiannogo skleroza na baze Gorodskoĭ klinicheskoĭ bol'nitsy #11

Khoroshylova I.I.

OOO «Neuroclinica», Moscow, Russia

Petrov S.V.

North-Western State Medical University named after I.I. Mechnikov, Saint-Petersburg, Russia, Elizabethan hospital, Saint-Petersburg, Russia

Lashch N.Iu.

Kafedra nevrologii i neĭrokhirurgii Rossiĭskogo natsional'nogo issledovatel'skogo meditsinskogo universiteta

Guseva M.E.

GBOU VPO «Rossiĭskiĭ natsionalnyĭ issledovatelskiĭ meditsinskiĭ universitet im. N.I. Pirogova», Moskva

Boĭko A.N.

KGBUZ "Krasnoiarskiĭ kraevoĭ Tsentr po profilaktike i bor'be so SPID i infektsionnymi zabolevaniiami"

Scopus AuthorID: 57224826008
ORCID: 0000-0001-6476-6417

List of references:

Boyko AN, Gusev EI. Current algorithms of diagnosis and treatment of multiple sclerosis based on the individual assessment of the patient. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2017;117(2):92-106. (In Russ.)
Soerensen PS. New management algorithms in multiple sclerosis. Curr Opin Neurol. 2014;27(3):246-259. https://doi.org/10.1097/WCO.0000000000000096
Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L. OPERA I and OPERA II Clinical Investigators. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med. 2017;376(3):221-234. https://doi.org/10.1056/NEJMoa1601277
Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS. ORATORIO Clinical Investigators Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med. 2017;376(3):209-220. https://doi.org/10.1056/NEJMoa1606468
Hauser SL, Belachew S, Kappos L. Ocrelizumab in primary progressive and relapsing multiple sclerosis. N Engl J Med. 2017;376(17):1694. https://doi.org/10.1056/NEJMc1702076
Kappos L, De Stefano N, Freedman MS, Cree BA, Radue EW, Sprenger T, Sormani MP, Smith T, Häring DA, Piani Meier D, Tomic D. Inclusion of brain volume loss in a revised measure of «no evidence of disease activity» (NEDA-4) in relapsing-remitting multiple sclerosis. Mult Scler. 2016;22(10):1297-1305. https://doi.org/10.1177/1352458515616701
Lehmann-Horn K, Kinzel S, Weber MS. Deciphering the Role of B Cells in Multiple Sclerosis-Towards Specific Targeting of Pathogenic Function. Int J Mol Sci. 2017;18(10):2048. https://doi.org/10.3390/ijms18102048
Mulero P, Midaglia L, Montalban X. Ocrelizumab: a new milestone in multiple sclerosis therapy. Ther Adv Neurol Disord. 2018;11:1756286418773025. https://doi.org/10.1177/1756286418773025
Yang H, Duchesneau E, Foster R, Guerin A, Ma E, Thomas NP. Cost-effectiveness analysis of ocrelizumab versus subcutaneous interferon beta-1a for the treatment of relapsing multiple sclerosis. J Med Econ. 2017;20(10):1056-1065. https://doi.org/10.1080/13696998.2017
Ireland SJ, Blazek M, Harp CT, Greenberg B, Frohman EM, Davis LS, Monson NL. Antibody-independent B cell effector functions in relapsing remitting multiple sclerosis: clues to increased inflammatory and reduced regulatory B cell capacity. Autoimmunity. 2012;45(5):400-414. https://doi.org/10.3109/08916934.2012.665529
Hultin LE, Hausner MA, Hultin PM, Giorgi JV. CD20 (pan-B cell) antigen is expressed at a low level on a subpopulation of human T lymphocytes. Cytometry. 1993;14:196-204.
Mease PJ. B cell-targeted therapy in autoimmune disease: rationale, mechanisms, and clinical application. J Rheumatol. 2008;35:1245-1255.
Palanichamy A, Jahn S, Nickles D, Derstine M, Abounasr A, Hauser SL, Baranzini SE, Leppert D, von Büdingen HC. Rituximab efficiently depletes increased CD20-expressing T cells in multiple sclerosis patients. J Immunol. 2014;193:580-586. https://doi.org/10.4049/jimmunol.1400118
Frau J, Coghe G, Lorefice L, Fenu G, Cocco E. New horizons for multiple sclerosis therapeutics: milestones in the development of ocrelizumab. Neuropsychiatr Dis Treat. 2018;14:1093-1099. https://doi.org/10.2147/NDT.S147874
Graves J, Vinayagasundaram U, Mowry EM, Matthews IR, Marino JA, Cheng J, Waubant E. Effects of rituximab on lymphocytes in multiple sclerosis and neuromyelitis optica. Multiple Sclerosis and Related Disorders. 2014;3(2):244-252. https://doi.org/10.1016/j.msard.2013.10.003
Weber MS, Prod’homme T, Patarroyo JC, Molnarfi N, Karnezis T, Lehmann-Horn K, Danilenko DM, Eastham-Anderson J, Slavin AJ, Linington C, Bernard CC, Martin F, Zamvil SS. B-cell activation influences T cell polarization and outcome of anti-CD20 B-cell depletion in central nervous system autoimmunity. Ann Neurol. 2010;68(3):369-383. https://doi.org/10.1002/ana.22081
Milo R. Therapeutic strategies targeting B-cells in multiple sclerosis. Autoimmun Rev. 2016;15:714-718.
Popova EV, Boĭko AN, Khachanova NV, Sharanova SN. Epstein—Barr virus in the pathogenesis of multiple sclerosis (a review). Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2014;114(2):29-34. (In Russ.)
Sundström P. Managing Epstein—Barr virus and other risk factors in MS-Future perspectives. Acta Neurol Scand. 2017;136(suppl 201):31-33. https://doi.org/10.1111/ane.12841
Serafini B, Scorsi E, Rosicarelli B, Rigau V, Thouvenot E, Aloisi F. Massive intracerebral Epstein-Barr virus reactivation in lethal multiple sclerosis relapse after natalizumab withdrawal. J Neuroimmunol. 2017;307:14-17. https://doi.org/10.1016/j.jneuroim.2017.03.013
Serafini B, Zandee S, Rosicarelli B, Scorsi E, Veroni C, Larochelle C, D’Alfonso S, Prat A, Aloisi F. Epstein-Barr virus-associated immune reconstitution inflammatory syndrome as possible cause of fulminant multiple sclerosis relapse after natalizumab interruption. J Neuroimmunol. 2018;319:9-12. https://doi.org/10.1016/j.jneuroim.2018.03.011
Hassani A, Corboy JR, Al-Salam S, Khan G. Epstein-Barr virus is present in the brain of most cases of multiple sclerosis and may engage more than just B cells. PLoS One. 2018;13(2):e0192109. https://doi.org/10.1371/journal.pone.0192109
Serafini B, Rosicarelli B, Magliozzi R, Stigliano E, Aloisi F. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol. 2004;14(2):164-174.
Demaerel P, Robberecht W, Casteels I, Wilms G, Medaer R, Carton H, Baert AL. Focal leptomeningeal MR enhancement along the chiasm as a presenting sign of multiple sclerosis. J Comput Assist Tomogr. 1995;19(2):297-298.
Avasarala J. Leptomeningeal enhancement for multiple sclerosis: another radiological biomarker for a relapse? JAMA Neurol. 2017;74(6):745-746. https://doi.org/10.1001/jamaneurol.2017.0123
Absinta M, Vuolo L, Rao A, Nair G, Sati P, Cortese IC, Ohayon J, Fenton K, Reyes-Mantilla MI, Maric D, Calabresi PA, Butman JA, Pardo CA, Reich DS Gadolinium-based MRI characterization of leptomeningeal inflammation in multiple sclerosis. Neurology. 2015;85(1):18-28. https://doi.org/10.1212/WNL.0000000000001587
Magliozzi R, Howell O, Vora A, Serafini B, Nicholas R, Puopolo M, Reynolds R, Aloisi F. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain. 2007;130:1089-1104.
Gardner C, Magliozzi R, Durrenberger PF, Howell OW, Rundle J, Reynolds R. Cortical grey matter demyelination can be induced by elevated pro-inflammatory cytokines in the subarachnoid space of MOG-immunized rats. Brain. 2013;136(12):3596-3608. https://doi.org/10.1093/brain/awt279
Zivadinov R, Ramasamy DP, Vaneckova M, Gandhi S, Chandra A, Hagemeier J, Bergsland N, Polak P, Benedict RH, Hojnacki D, Weinstock-Guttman B. Leptomeningeal contrast enhancement is associated with progression of cortical atrophy in MS: A retrospective, pilot, observational longitudinal study. Multiple Sclerosis J. 2016;23(10):1336-1345. https://doi.org/10.1177/1352458516678083
Eisele P, Griebe M, Szabo K, Wolf ME, Alonso A, Engelhardt B, Hennerici MG, Gass A. Investigation of leptomeningeal enhancement in MS: a postcontrast FLAIR MRI study. Neurology. 2015;84(8):770-775. https://doi.org/10.1212/WNL.0000000000001286
Harrison DM, Wang KY, Fiol J, Naunton K, Royal W 3rd, Hua J, Izbudak I. Leptomeningeal enhancement at 7T in multiple sclerosis: frequency, morphology, and relationship to cortical volume. J Neuroimaging. 2017;27(5):461-468. https://doi.org/10.1111/jon
Makshakov G, Magonov E, Totolyan N, Nazarov V, Lapin S, Mazing A, Verbitskaya E, Trofimova T, Krasnov V, Shumilina M, Skoromets A, Evdoshenko E. Leptomeningeal Contrast Enhancement Is Associated with Disability Progression and Grey Matter Atrophy in Multiple Sclerosis. Neurol Res Int. 2017;2017:8652463. https://doi.org/10.1155/2017/8652463
von Budingen HC, Kuo TC, Sirota M, van Belle CJ, Apeltsin L, Glanville J, Cree BA, Gourraud PA, Schwartzburg A, Huerta G, Telman D, Sundar PD, Casey T, Cox DR, Hauser SL. B cell exchange across the blood-brain barrier in multiple sclerosis. J Clin Invest. 2012;122(12):4533-4543. https://doi.org/10.1172/JCI63842
Eisele P, Griebe M, Szabo K, Wolf ME, Alonso A, Engelhardt B, Hennerici MG, Gass A. Investigation of leptomeningeal enhancement in MS: A postcontrast FLAIR MRI study. Neurology. 2015;84(8):770-775. https://doi.org/10.1212/WNL.0000000000001286
Fukuoka H, Hirai T, Okuda T, Shigematsu Y, Sasao A, Kimura E, Hirano T, Yano S, Murakami R, Yamashita Y. Comparison of the added value of contrast-enhanced 3D fluid-attenuated inversion recovery and magnetization-prepared rapid acquisition of gradient echo sequences in relation to conventional postcontrast T1-weighted images for the evaluation of leptomeningeal diseases at 3T. Am J Neuroradiol. 2010;31(5):868-873. https://doi.org/10.3174/ajnr.A1937
Long Y, Chen M, Zhang B, Gao C, Zheng Y, Xie L, Gao Q, Yin J. Brain gadolinium enhancement along the ventricular and leptomeningeal regions in patients with aquaporin-4 antibodies in cerebral spinal fluid. J Neuroimmunol. 2014;269(1-2):62-67. https://doi.org/10.1016/j.jneuroim.2014.02.006
Absinta M, Cortese IC, Vuolo L, Nair G, de Alwis MP, Ohayon J, Meani A, Martinelli V, Scotti R, Falini A, Smith BR, Nath A, Jacobson S, Filippi M, Reich DS. Leptomeningeal gadolinium enhancement across the spectrum of chronic neuroinflammatory diseases. Neurology. 2017;88(15):1439-1444. https://doi.org/10.1212/WNL.0000000000003820
Boyko AN., Davydovskaya MV., Hachanova NV., Zaharova MN., Spirin NN., Popova EV., Alifirova VM., Vlasov YaV., Sivertseva SA., Habirov FA., Shumilina MV., Evdoshenko EP. Klinicheskie rekomendatsii po primeneniyu preparata okrelizumab u patsientov s rasseyannym sklerozom. https://www.ructrims.org/files/Klinicheskie_rekomendacii_po%20primeneniyu_preparata_okrelizumab_2018.pdf https://www.ructrims.org/files/Клинические_рекомендации_по%20применению_препарата_окрелизумаб_2018.pdf

Close metadata